Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST

被引：0
|
作者：
Inga-Marie Schaefer
Matthew L. Hemming
Meijun Z. Lundberg
Matthew P. Serrata
Isabel Goldaracena
Ninning Liu
Peng Yin
Joao A. Paulo
Steven P. Gygi
Suzanne George
Jeffrey A. Morgan
Monica M. Bertagnolli
Ewa T. Sicinska
Chen Chu
Shanshan Zheng
Adrian Mariño-Enríquez
Jason L. Hornick
Chandrajit P. Raut
Wen-Bin Ou
George D. Demetri
Sinem K. Saka
Jonathan A. Fletcher
机构：
[1] Harvard Medical School,Department of Pathology, Brigham and Women’s Hospital
[2] Dana-Farber Cancer Institute and Harvard Medical School,Department of Medical Oncology
[3] Dana-Farber Cancer Institute and Brigham and Women’s Hospital,Sarcoma Center
[4] Harvard University,Wyss Institute for Biologically Inspired Engineering
[5] Harvard Medical School,Department of Cell Biology
[6] Brigham and Women’s Hospital,Department of Surgery
[7] Harvard Medical School,Department of Pathology
[8] Dana-Farber Cancer Institute,Department of Cancer Biology
[9] Harvard Medical School,Department of Genetics
[10] Dana-Farber Cancer Institute,Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine
[11] Blavatnik Institute,Ludwig Center at Harvard
[12] Harvard Medical School,European Molecular Biology Laboratory (EMBL)
[13] Zhejiang Sci-Tech University,undefined
[14] Harvard Medical School,undefined
[15] Genome Biology Unit,undefined
来源：
British Journal of Cancer | 2022年 / 127卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2072 / 2085
页数：13
相关论文
共 50 条
  • [11] Combined inhibition of CDK2 and CDK4/6 overcomes acquired resistance to CDK4/6 inhibitors in breast cancer via RB-independent pathway
    Pandey, Kamal
    CANCER RESEARCH, 2020, 80 (16)
  • [12] C/EBPα arrests cell proliferation through direct inhibition of cdk2 and cdk4
    Wang, HM
    Iakova, P
    Wilde, M
    Welm, A
    Goode, T
    Roesler, WJ
    Timchenko, NA
    MOLECULAR CELL, 2001, 8 (04) : 817 - 828
  • [13] Unexpected Outcomes of CDK4/6 Inhibition
    Choi, Yoon Jong
    Sicinski, Piotr
    ONCOTARGET, 2013, 4 (02) : 176 - 177
  • [14] Resistance mechanisms to CDK4/6 Inhibition
    O'Leary, Ben
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 589 - 589
  • [15] TY-0540, a highly potent CDK2/4/6 inhibitor, attenuates acquired resistance against CDK4/6 inhibition
    Li, Meihua
    Niu, Chengshan
    Chen, Mingtao
    Ji, Kaige
    Xu, Hui
    Dong, Shengli
    Zhang, Yan
    Meng, Qinguo
    Dou, Yuge
    Wang, Yijun
    Wu, Rui
    Tu, Yian
    Zhou, Chao
    Liang, Apeng
    Wang, Huan
    Ni, Rongzhen
    Gong, Aishen
    Su, Hui
    Jiang, Mingyu
    Xing, Feng
    Chen, Shaoqing
    Chen, Xiugui
    Li, Jun
    Wu, Yusheng
    CANCER RESEARCH, 2023, 83 (07)
  • [16] Mice thrive without Cdk4 and Cdk2
    Barriere, Cedric
    Santamaria, David
    Cerqueira, Antonio
    Galan, Javier
    Martin, Alberto
    Ortega, Sagrario
    Malumbres, Marcos
    Dubus, Pierre
    Barbacid, Mariano
    MOLECULAR ONCOLOGY, 2007, 1 (01): : 72 - 83
  • [17] CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard
    Wolff, Antonio C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20): : 1993 - 1995
  • [18] Application of CDK4/6 inhibition therapies to PDACs
    Zhang, Yuanyuan
    CANCER SCIENCE, 2023, 114 : 1937 - 1937
  • [19] Inhibition of CDK1/2 but not CDK4/6 cooperates with tamoxifen to induce apoptosis
    Scott, Gary K.
    Rothschild, Daniel
    Kaur, Ravneet
    Benz, Christopher
    CANCER RESEARCH, 2014, 74 (19)
  • [20] Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
    Alvarez-Fernandez, Monica
    Malumbres, Marcos
    CANCER CELL, 2020, 37 (04) : 514 - 529
12345